Biopsy News and Research

RSS

Biopsy is the removal of cells or tissues for examination by a pathologist. The pathologist may study the tissue under a microscope or perform other tests on the cells or tissue. There are many different types of biopsy procedures. The most common types include: (1) incisional biopsy, in which only a sample of tissue is removed; (2) excisional biopsy, in which an entire lump or suspicious area is removed; and (3) needle biopsy, in which a sample of tissue or fluid is removed with a needle. When a wide needle is used, the procedure is called a core biopsy. When a thin needle is used, the procedure is called a fine-needle aspiration biopsy.

Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

Genomic Health, Inc. today announced the presentation of two studies at the American Society of Clinical Oncology® (ASCO®) Genitourinary (GU) Cancer Symposium, including complete results from its prostate cancer gene identification study, which identified 295 genes strongly associated with clinical recurrence following radical prostatectomy with great consistency across multiple tumor samples examined in each patient.

17 Feb 2011

Cook Medical launches new histology needle for endoscopic ultrasound

A new histology needle for endoscopic ultrasound (EUS) from Cook Medical is now on the market, giving physicians the ability to retrieve tissue samples from hard-to-reach regions within or adjacent to the GI tract with a minimally invasive procedure.

17 Feb 2011

Medtronic: Kyphon Balloon Kyphoplasty provides better back pain relief in cancer patients

Medtronic Inc., today announced the results of the first randomized, controlled trial comparing Kyphon Balloon Kyphoplasty with non-surgical care in treating spinal fractures in cancer patients. The study found that Kyphon Balloon Kyphoplasty provided cancer patients better back-specific function, more rapid back pain relief and improved quality of life compared with non-surgical care one month after treatment.

17 Feb 2011

New clinical trial to test surgery specifically for Type 2 diabetes

A new clinical trial at NewYork-Presbyterian Hospital/Weill Cornell Medical Center is among the first to test surgery specifically for Type 2 diabetes. The aim of the study is to understand whether surgery can control diabetes, as well or even better than the best medical treatment available today. This is the first study of its kind open to patients who are overweight or mildly obese.

14 Feb 2011

FDA approves Hologic's 3-D digital mammography system to diagnose breast cancer

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the Company received approval from the U.S. Food and Drug Administration for its Selenia Dimensions digital breast tomosynthesis system.

From Hologic, Inc. 14 Feb 2011

Genetic map for prostate cancer

Researchers have managed to uncover the whole genetic sequence in prostate cancer. This complete map, hope researchers, will eventually lead to the development of more targeted drugs and a better understanding of which prostate cancers are likely to spread, one of the biggest challenges for physicians and patients.

13 Feb 2011

Genes for prostate cancer mapped for the first time

A genetic blue print that uncovers many of the mutations and genetic damage that drives prostate cancer and could lead to new treatments and better diagnosis has been found. This would mean earlier detection and new breeds of drugs to reverse the damage. Also each patient could have his own “cancer chart” made so that his treatment is personalized. The study, conducted by researchers from the Broad Institute, Dana-Farber Cancer Institute and Weill Cornell Medical College, appears in the Feb. 10 issue of Nature.

13 Feb 2011

New trial tests surgery for Type 2 diabetes

11 Feb 2011

Full genetic blueprint of multiple prostate tumors laid bare

For the first time, researchers have laid bare the full genetic blueprint of multiple prostate tumors, uncovering alterations that have never before been detected and offering a deep view of the genetic missteps that underlie the disease. The study, made possible by key advances in whole genome sequencing and analysis, points to several new prostate cancer genes and a critical category of genomic changes as important drivers of prostate cancer growth.

10 Feb 2011

New rotary-powered device for bone marrow aspiration, biopsy yields superior samples with less pain

For many cancer patients, a bone marrow biopsy and/or aspiration is one of the most dreaded aspects of their diagnosis and treatment plan. The traditional method for gaining bone marrow involves grinding a needle by hand through a patient's skin and bone, and the procedure is often described as extremely painful.

10 Feb 2011

Men with high levels of CCP genes more likely to have fatal form of prostate cancer

A genetic pattern could predict how aggressive prostate cancer is before treatment, and whether the disease will come back in men who have already been treated, according to research published1 in the Lancet Oncology.

9 Feb 2011

Study shows dogs can be trained to detect PCa by smelling urine

In the February 2011 issue of European Urology, Jean-Nicolas Cornu and colleagues reported the evaluation of the efficacy of prostate cancer detection by trained dogs on human urine samples.

8 Feb 2011

British Journal of Dermatology publishes data on DermTech's new genomic assay for melanoma

DermTech International, a biotechnology company dedicated to bringing genomic medicine to dermatologists, today announced that the discovery data on its new genomic assay for melanoma have been published in the British Journal of Dermatology.

7 Feb 2011

Hologic receives FDA approval for hydroxyprogesterone caproate injection

Hologic, a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the U.S. Food and Drug Administration has approved Hologic's pharmaceutical named Makena, formerly known as Gestiva.

From Hologic, Inc. 4 Feb 2011

More careful regulation of FDA's Humanitarian Device Exemption in psychiatric patients needed

Warning that patients could be at risk, an interdisciplinary group of multinational investigators is calling on the U.S. Congress and federal regulators to tighten a law that permits use of brain devices to treat rare neuropsychiatric disorders without supporting clinical trials or stringent patient oversight.

4 Feb 2011

First blood-based diagnostic test for LAM

Circadian Technologies has announced today that in conjunction with Cincinnati Children's Hospital Medical Center it has begun offering its LAM diagnostic, which is offered as a laboratory test compliant with CAP (College of American Pathologists) /CLIA regulations.

2 Feb 2011

Researchers find better way to create iPS cells from blood samples

Researchers at Johns Hopkins have found a better way to create induced pluripotent stem cells-adult cells reprogrammed with the properties of embryonic stem cells-from a small blood sample. This new method, described last week in Cell Research, avoids creating DNA changes that could lead to tumor formation.

2 Feb 2011

Microbubble contrast- enhanced ultrasound improves identification of sentinel lymph node in breast biopsies

Using "microbubbles" and ultrasound can mean more targeted breast biopsies for patients with early breast cancer, helping to determine treatment and possibly saving those patients from undergoing a second breast cancer surgery, a new study in shows.

2 Feb 2011

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

Positron emission tomography can image metabolic changes following treatment with the protein kinase inhibitor vandetanib, helping to define the therapy response or the effectiveness of the therapeutic agent, according to research published in the February issue of The Journal of Nuclear Medicine.

1 Feb 2011

Kensey Nash second quarter revenue decreases to $17.4 million

Kensey Nash Corporation, a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its second quarter ended December 31, 2010.

1 Feb 2011

Biopsy News and Research

Further Reading

Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

Cook Medical launches new histology needle for endoscopic ultrasound

Medtronic: Kyphon Balloon Kyphoplasty provides better back pain relief in cancer patients

New clinical trial to test surgery specifically for Type 2 diabetes

FDA approves Hologic's 3-D digital mammography system to diagnose breast cancer

Genetic map for prostate cancer

Genes for prostate cancer mapped for the first time

New trial tests surgery for Type 2 diabetes

Full genetic blueprint of multiple prostate tumors laid bare

New rotary-powered device for bone marrow aspiration, biopsy yields superior samples with less pain

Men with high levels of CCP genes more likely to have fatal form of prostate cancer

Study shows dogs can be trained to detect PCa by smelling urine

British Journal of Dermatology publishes data on DermTech's new genomic assay for melanoma

Hologic receives FDA approval for hydroxyprogesterone caproate injection

More careful regulation of FDA's Humanitarian Device Exemption in psychiatric patients needed

First blood-based diagnostic test for LAM

Researchers find better way to create iPS cells from blood samples

Microbubble contrast- enhanced ultrasound improves identification of sentinel lymph node in breast biopsies

PET imaging may play a role in early evaluation of vandetanib response in thyroid cancer

Kensey Nash second quarter revenue decreases to $17.4 million

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News